News stories about Stellar Biotechnologies (NASDAQ:SBOT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stellar Biotechnologies earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.8245360688277 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Stellar Biotechnologies stock traded down $0.03 during trading hours on Thursday, reaching $1.79. 143,481 shares of the stock were exchanged, compared to its average volume of 320,780. The company has a market cap of $6.06 million, a P/E ratio of -0.52 and a beta of 0.22. Stellar Biotechnologies has a 52-week low of $1.72 and a 52-week high of $10.85.
Separately, ValuEngine upgraded shares of Stellar Biotechnologies from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 8th.
Stellar Biotechnologies, Inc, a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market.
Receive News & Ratings for Stellar Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.